Get the Stockscreener App
25.22
4.97%
-1.32
Xoma Royalty Corp stock is traded at $25.22, with a volume of 133.63K.
It is down -4.97% in the last 24 hours and down -24.99% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
See More
Previous Close:
$26.54
Open:
$26.82
24h Volume:
133.63K
Relative Volume:
2.28
Market Cap:
$312.30M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-7.2471
EPS:
-3.48
Net Cash Flow:
$-14.79M
1W Performance:
-15.68%
1M Performance:
-24.99%
6M Performance:
+2.52%
1Y Performance:
-10.02%
1-Day Range:
$25.07
$27.16
1-Week Range:
$25.07
$34.79
52-Week Range:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
25.22 | 328.65M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | The Benchmark Company | Buy |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat
XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com
XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus
Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Canada
XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
Lucid Capital Markets initiates coverage on XOMA stock with Buy rating - Investing.com Canada
XOMA Royalty (XOMA): New Buy Rating Initiated by Lucid Capital M - GuruFocus
Mural Oncology Announces Sanction of the Scheme by the High Court - 富途牛牛
XOMA (NASDAQ:XOMAO) Trading 0.8% Higher – Time to Buy? - Defense World
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma announces closing of transaction to acquire Mural Oncology - TipRanks
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
Mural Oncology Plc Completes Acquisition by XRA 5 Corp. - TipRanks
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - Yahoo Finance
XOMA Royalty completes acquisition of Mural Oncology - Investing.com India
Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) scheme with XOMA unit effective as Nasdaq listing ends - Stock Titan
Why XOMA Royalty Corporation (X0M1) stock could be top winnerJuly 2025 Outlook & Weekly High Return Stock Opportunities - Newser
Will XOMA Royalty Corporation (X0M1) stock test record highs in 20252025 Price Action Summary & Weekly High Return Forecasts - Newser
Why XOMA Royalty Corporation (X0M1) stock appeals to dividend investorsEarnings Recap Report & Capital Efficient Trade Techniques - Newser
What earnings margins imply for XOMA Royalty Corporation(X0M) stockIPO Watch & Risk Managed Investment Strategies - Newser
Irish court approves XOMA Royalty’s acquisition of Mural Oncology By Investing.com - Investing.com India
Irish court approves XOMA Royalty’s acquisition of Mural Oncology - Investing.com
Mural Oncology plc Announces Court Approval of Scheme for Acquisition by XOMA Royalty Corporation's Subsidiary - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) wins Irish court nod for XOMA deal, Nasdaq trading expected to end Dec. 4 - Stock Titan
Is XOMA Royalty Corporation (X0M1) stock a defensive play amid uncertaintyMarket Activity Summary & Weekly Watchlist for Consistent Profits - Newser
How robust is XOMA Royalty Corporation(X0M) stock financial position - Newser
XOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition - Nasdaq
Mural Oncology announces final cash consideration payable on acquisition close - MSN
XOMA Royalty to acquire Mural Oncology for $2.035 per share By Investing.com - Investing.com Nigeria
XOMA Royalty to acquire Mural Oncology for $2.035 per share - Investing.com India
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty - The Globe and Mail
Mural Oncology plc Announces Final Determination of Additional Price Per Share in Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) to Be Acquired by XOMA Royalty for $2.035 Cash - Stock Titan
XOMA (NASDAQ:XOMAP) Trading 0.2% Higher – Should You Buy? - Defense World
Xoma completes $24.9M acquisition of cash-strapped Lava Therapeutics - The Business Journals
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - ADVFN
Xoma announces closing of transactions to acquire Lava Therapeutics - TipRanks
XOMA Royalty completes acquisition of LAVA Therapeutics - Investing.com
[8-K] XOMA Royalty Corp Reports Material Event - Stock Titan
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):